Eli Lilly and Co (XBUL:LLY)
лв 750.5 0 (0%) Market Cap: 1.38 Tn Enterprise Value: 1.43 Tn PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 66/100

Eli Lilly and Co at Guggenheim Healthcare Talks Oncology Day Transcript

Feb 09, 2023 / 03:10PM GMT
Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

All right. Thanks, everybody. I'm Seamus Fernandez, the global biopharma analyst here at Guggenheim Securities. This is our Fifth Annual Oncology Conference.

Really pleased to be joined by Eli Lilly. To my far left is Jake Van Naarden, CEO of Loxo Oncology at Lilly and President, Lilly Oncology; and Dr. David Hyman, immediately to my left here, is Chief Medical Officer of Lilly Oncology.

Questions & Answers

Seamus Christopher Fernandez
Guggenheim Securities, LLC, Research Division - Senior Analyst of Global Pharmaceuticals

So Jake, maybe just to kick us off, you can give us a little bit of a sense of key drivers. I think we were just talking about how impressive a quarter we just saw out of Verzenio, but maybe I'll leave it for you to take it away from there.

Jacob S. Van Naarden
Eli Lilly and Company - Senior VP, CEO of Loxo Oncology & President of Lilly Oncology

Yes,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot